Alpha-GPC

Alpha-GPC, also called choline alfoscerate or L-alpha glycerylphosphorylcholine, is a naturally occurring choline-containing phospholipid and a semisynthetic derivative of phosphatidylcholine ^[7]. It sits among several cholinergic compounds, alongside citicoline, choline bitartrate, and lecithin, that serve as precursors to acetylcholine, but it is distinguished by high bioavailability and by its ability to cross the blood-brain barrier and deliver choline directly to neurons ^[3]. Structurally it consists of a choline moiety linked through a phosphate group to a glycerol backbone, and on metabolism it releases free choline while its glycerophosphate portion feeds membrane phospholipid synthesis.

Alpha-GPC was first developed and granted marketing authorization in 1985 and has been used in parts of Europe as a prescription medicine for cognitive impairment of neurodegenerative and vascular origin ^[2]. In several clinical studies it improved cognition, function, and behavior in adults with dementia disorders, and a 2023 systematic review and meta-analysis found that alpha-GPC, alone or combined with the acetylcholinesterase inhibitor donepezil, significantly improved cognitive outcomes ^[2]. In healthy adults, acute supplementation has been reported to enhance measures of attention and processing speed, and it is studied as a nootropic and as an ergogenic aid tied to power output and the growth hormone response ^[1][4]. Preclinical work additionally describes neuroprotective and neurogenic effects in models of injury, stress, and seizure ^[6].

Regulatory status differs by region; in the United States and many other markets alpha-GPC is sold as a dietary supplement or nutraceutical rather than an approved drug, while some European countries classify it as a prescription medicine ^[2][3]. It is available in capsule, powder, and liquid forms, is frequently combined with racetams and other nootropics, and is valued for a favorable tolerability profile.

Alpha-GPC is easy to tolerate for most people and sits on shelves as a supplement in the US, EU, and Japan. Skip it if you react to choline or soy, since a lot of products are made from soy. Don't pair it with anticholinergics like diphenhydramine, scopolamine, or tricyclics; they pull in the opposite direction and cancel it out. If you're already on an acetylcholinesterase inhibitor (donepezil, rivastigmine, huperzine A), go easy, because stacking cholinergic load can leave you nauseous, slow your heart rate, or make you salivate.

Same caution with CDP-choline; doubling up on choline can tip you into excess, which shows up as lethargy, low mood, or a fishy body odor. One 2021 observational study floated a possible link between heavy Alpha-GPC use and stroke risk in older adults, but it's still debated and far from proven. More specifically, that signal is thought to run through TMAO: Alpha-GPC feeds gut production of TMAO, and some studies tie that to roughly a 46 percent higher stroke risk in older adults. It is still observational, but if you are heart-conscious it is worth weighing, and choline sources that raise TMAO less may be preferable.

Alpha-GPC is a choline donor that raises central acetylcholine, and its best-documented pairing is adjunctive use with the cholinesterase inhibitor donepezil in Alzheimer's trials (the ASCOMALVA study), where the combination was investigated for additive cholinergic benefit rather than as an adverse interaction. On the same mechanistic basis, a theoretical additive cholinergic effect exists when it is combined with other cholinesterase inhibitors or direct cholinergic agents, and a theoretical opposing interaction exists with anticholinergic drugs such as scopolamine; neither is established as clinically significant in controlled human interaction studies. Beyond the cholinergic axis there is no robust documented drug-interaction dataset for alpha-GPC. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

Alpha-GPC, or L-alpha glycerylphosphorylcholine, is a naturally occurring choline-containing phospholipid found in the body and in trace amounts in foods such as milk. As a purified compound it was developed for clinical use under the name choline alphoscerate and received marketing authorization as a medicine in 1985, chiefly in parts of Europe where it is prescribed for cognitive decline associated with cerebrovascular conditions. Regulatory status has diverged since then; in some countries it is a prescription drug, while in the United States it is sold as a dietary supplement and nootropic. It is manufactured today both as a cognitive agent and as an ingredient in sports nutrition products.

Alpha-GPC enjoys a strong reputation as one of the more evidence-supported cholinergic supplements, prized for its high bioavailability and ability to cross the blood-brain barrier to supply choline for acetylcholine synthesis. A 2023 systematic review and meta-analysis found that it improved cognition relative to comparators, particularly when combined with the Alzheimer's drug donepezil, lending clinical weight to its long-standing pharmaceutical use. Beyond cognition, it is popular among athletes for reports that it can support power output and stimulate growth hormone release. It is generally well tolerated, though the same meta-analysis and its authors are careful to note that much of the strongest evidence comes from older or cerebrovascular-injury populations rather than healthy young users.